BCM
MIST icon

BML Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

BML Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,136,091
Closed -$2.2M – 24
2025
Q2 		$2.2M Hold
1,136,091
– – 1.67% 13
2025
Q1 		$909K Hold
1,136,091
– – 0.74% 19
2024
Q4 		$2.68M Hold
1,136,091
– – 1.67% 14
2024
Q3 		$1.73M Buy
1,136,091
+33,196
+3% +$48.3K 1.02% 16
2024
Q2 		$1.46M Buy
1,102,895
+496,750
+82% +$798K 1.04% 16
2024
Q1 		$1.08M Buy
606,145
+163,793
+37% +$266K 0.72% 22
2023
Q4 		$739K Buy
442,352
+169,852
+62% +$461K 0.56% 25
2023
Q3 		$845K Hold
272,500
– – 0.78% 15
2023
Q2 		$777K Buy
272,500
+52,500
+24% +$198K 0.7% 22
2023
Q1 		$867K Buy
220,000
+40,000
+22% +$146K 0.75% 25
2022
Q4 		$713K Buy
+180,000
New +$948K 0.68% 19

Other funds holding MIST

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BML Capital Management's MIST Position: Q3 2025 in Review

BML Capital Management sold out of Milestone Pharmaceuticals (MIST) in Q3 2025, closing a stake of 1,136,091 shares — an estimated $2.2M sold.

BML Capital Management first reported a position in MIST in Q4 2022 and held it in 11 quarters. The position peaked at $2.68M in Q4 2024. 61 funds tracked by Wall St. Rank hold MIST as of Q3 2025.

  • BML Capital Management reported no remaining Milestone Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • BML Capital Management sold 1,136,091 Milestone Pharmaceuticals shares in Q3 2025, an estimated $2.2M.
  • BML Capital Management first reported a position in Milestone Pharmaceuticals in Q4 2022 and held it in 11 quarters.
  • BML Capital Management's Milestone Pharmaceuticals position peaked at $2.68M in Q4 2024.
  • 61 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q3 2025.

Based on BML Capital Management's 13F filing for Q3 2025, filed 10 Nov 2025.